82 FR 16404 - Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

Federal Register Volume 82, Issue 63 (April 4, 2017)

Page Range		16404-16405
FR Document		2017-06536

Federal Register, Volume 82 Issue 63 (Tuesday, April 4, 2017)

[Federal Register Volume 82, Number 63 (Tuesday, April 4, 2017)]
[Notices]
[Pages 16404-16405]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-06536]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Initial Review

    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces a meeting for the initial review of 
applications in response to Funding Opportunity Announcement (FOA) 
DP17-001, Community Characteristics Associated with Geographic 
Disparities in Diabetes and Cardiometabolic Health.
    Times and Dates:

10:00 a.m.-6:00 p.m., EDT, April 25, 2017 (Closed)
10:00 a.m.-6:00 p.m., EDT, April 26, 2017 (Closed)

    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance with 
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., 
and the Determination of the Director, Management Analysis and Services 
Office, CDC, pursuant to Public Law 92-463.
    Matters for Discussion: The meeting will include the initial 
review,

[[Page 16405]]

discussion, and evaluation of applications received in response to 
``Community Characteristics Associated with Geographic Disparities in 
Diabetes and Cardiometabolic Health'', DP17-001.
    Contact Person for More Information: Jaya Raman Ph.D., Scientific 
Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta, 
Georgia 30341, Telephone: (770) 488-6511, kva5@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2017-06536 Filed 4-3-17; 8:45 am]
 BILLING CODE 4163-18-P

16404 Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices

strategy of pre-exposure prophylaxis The study population will include changes in condom use behavior,
(PrEP) for HIV-negative MSM who are at 1,206 adult MSM living in Atlanta, GA, number of sex partners, HIV testing,
high risk of contracting HIV. For Detroit, MI and New York City, NY. sexually transmitted disease (STD)
maximum efficacy, health These study sites were selected not only testing, health care engagement, pre-
communications about HIV prevention because they have high rates of HIV, but exposure prophylaxis uptake and
and control should be delivered to MSM also because significant disparities in adherence, and antiretroviral therapy
according to their HIV serostatus and HIV among men who have sex with men uptake and adherence following
risk category. (MSM) have been observed by race/ completion of the intervention.
The National Center for HIV/AIDS, ethnicity and age. Study participants Participants will complete the
Viral Hepatitis, STD and TB Prevention will be sexually active MSM at least 18 assessment in-person at baseline and 9-
is requesting approval to evaluate the years in age who own and use and months, using a computer in a private
efficacy of a smartphone-based HIV Android and iOS smartphone. Study location, and remotely via their personal
prevention intervention for MSM, participants will be stratified by risk computer or tablet device at the 3-
known as M3(M-Cubed) that has been category: HIV positive (one third) and month and 6-month follow-ups. The
designed to deliver targeted messages in HIV negative (one third each: same information will be collected from
six intervention domains: HIV testing, condomless anal sex in past three all participants. The burden per
sexually transmitted infection (STI) months; no condomless anal sex past response for each assessment is 1.5
testing, PrEP, antiretroviral (ARV) three months). Across the three sites, we hours.
treatment, Condoms, and Engagement in will ensure that at least 40% of It is expected that 50% of men
Care. The smartphone and tablet participants are people of color (non- screened will meet study eligibility and
application includes 36 core messages white or Hispanic) by quota sampling. provide contact information, that 75
and 12 videos that were developed Participants will be recruited to the percent will schedule and show up for
based on CDC-sponsored iterative study through a combination of an in-person appointment, and that 95
formative research (OMB No. 0920– approaches, including online percent of these men will remain
0840) and a review of HIV health advertisement, traditional print eligible after reverification. We expect
communications literature. Messages advertisement, referral, in-person the initial screening to take
will be delivered to each participant’s outreach, and through word of mouth. approximately four minutes to
device. The proposed study will assess Participants will be randomly assigned complete, that providing contact
whether exposure to the message- to an intervention group or a waitlist information will take 1 minute, and the
delivery platform results in control group. The control group will rescreening prior to study enrollment to
improvements in participants’ self- receive the intervention after the study take another four minutes.
reported sexual health and HIV has been completed. OMB approval is requested for two
prevention behaviors, beliefs and A quantitative assessment years. Participation is voluntary and
attitudes. Information will be collected questionnaire will be administered there are no costs to the respondents
at baseline and 3-month, 6-month, and online at four points in time. The other than their time. The total
9-month follow-ups. assessment will be used to measure estimated annual burden is 3,787 hours.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of Average
Number of responses burden per
Type of respondent Form name respondents per response
respondent (in hours)

Men ≥ 18 Years of Age Who Have Sex With Participant Screening (Eligibility) ................... 1,693 1 4/60
Men.
Contact Information Form .............................. 847 1 1/60
Participant Screening (Verification) ................ 635 1 4/60
Assessment .................................................... 603 4 1.5

Leroy A. Richardson, DEPARTMENT OF HEALTH AND Geographic Disparities in Diabetes and
Chief, Information Collection Review Office, HUMAN SERVICES Cardiometabolic Health.
Office of Scientific Integrity, Office of the Times and Dates:
Associate Director for Science, Office of the Centers for Disease Control and 10:00 a.m.–6:00 p.m., EDT, April 25,
Director, Centers for Disease Control and Prevention 2017 (Closed)
Prevention.
10:00 a.m.–6:00 p.m., EDT, April 26,
[FR Doc. 2017–06577 Filed 4–3–17; 8:45 am] Disease, Disability, and Injury
2017 (Closed)
BILLING CODE 4163–18–P
Prevention and Control Special
Emphasis Panel (SEP): Initial Review Place: Teleconference.
Status: The meeting will be closed to
In accordance with Section 10(a)(2) of the public in accordance with
asabaliauskas on DSK3SPTVN1PROD with NOTICES

the Federal Advisory Committee Act provisions set forth in Section 552b(c)
(Pub. L. 92–463), the Centers for Disease (4) and (6), Title 5 U.S.C., and the
Control and Prevention (CDC) Determination of the Director,
announces a meeting for the initial Management Analysis and Services
review of applications in response to Office, CDC, pursuant to Public Law 92–
Funding Opportunity Announcement 463.
(FOA) DP17–001, Community Matters for Discussion: The meeting
Characteristics Associated with will include the initial review,

VerDate Sep<11>2014 16:21 Apr 03, 2017 Jkt 241001 PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 E:\FR\FM\04APN1.SGM 04APN1

Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices 16405

discussion, and evaluation of Name of Committee: National Institute on Only written comments and/or
DATES:
applications received in response to Aging Initial Review Group, Neuroscience of applications for a license which are
‘‘Community Characteristics Associated Aging Review Committee, received by the NHLBI Office of
Date: June 1–2, 2017.
with Geographic Disparities in Diabetes Time: 2:00 p.m. to 2:00 p.m.
Technology Transfer and Development
and Cardiometabolic Health’’, DP17– Agenda: To review and evaluate grant on or before April 19, 2017 will be
001. applications. considered.
Contact Person for More Information: Place: Torrance Marriott Redondo Beach, ADDRESSES: Requests for copies of the
Jaya Raman Ph.D., Scientific Review 3635 Fashion Way, Torrance, CA 90503. patent application, inquiries, and
Contact Person: Jeannette L. Johnson,
Officer, CDC, 4770 Buford Highway, comments relating to the contemplated
Ph.D., Deputy Review Branch Chief, National
Mailstop F80, Atlanta, Georgia 30341, Institutes of Health, National Institute on exclusive license should be directed to:
Telephone: (770) 488–6511, kva5@ Aging, Gateway Building, Bethesda, MD Cristina Thalhammer-Reyero, Ph.D.,
cdc.gov. 20892, 301–402–7705, johnsonj9@ MBA, Senior Licensing and Patenting
The Director, Management Analysis nia.nih.gov. Manager, NHLBI Office of Technology
and Services Office, has been delegated Name of Committee: National Institute on Transfer and Development, 31 Center
the authority to sign Federal Register Aging Initial Review Group, Clinical Aging Drive Room 4A29, MSC2479, Bethesda,
Review Committee. MD 20892–2479; Telephone: +1–301–
notices pertaining to announcements of Date: June 1–2, 2017.
meetings and other committee 435–4507; Fax: +1–301–594–3080;
Time: 2:00 p.m. to 2:00 p.m. Email: thalhamc@mail.nih.gov.
management activities, for both the Agenda: To review and evaluate grant
Centers for Disease Control and applications. SUPPLEMENTARY INFORMATION: The
Prevention and the Agency for Toxic Place: Torrance Marriott Redondo Beach, following represents the intellectual
Substances and Disease Registry. 3635 Fashion Way, Torrance, CA 90503. property to be licensed under the
Contact Person: Alicja L. Markowska, prospective agreement:
Elaine L. Baker, Ph.D., Dsc., National Institute on Aging, U.S. Provisional Patent Application
Director, Management Analysis and Services National Institutes of Health, Gateway Serial No. 61/045,213, filed 04/15/2008;
Office, Centers for Disease Control and Building 2C212, 7201 Wisconsin Avenue, PCT Application No. PCT/US2009/
Prevention. Bethesda, MD 20892, 301–496–9666,
040560, filed 04/14/2009; U.S. Patent
[FR Doc. 2017–06536 Filed 4–3–17; 8:45 am] markowsa@nia.nih.gov.
Application Serial No.12/937,974,
(Catalogue of Federal Domestic Assistance
BILLING CODE 4163–18–P
Program Nos. 93.866, Aging Research,
issued as 8,936,787 on 01/20/2015;
National Institutes of Health, HHS) Titled ‘‘Peptides Promoting Lipid
Efflux’’ (NIH Reference No. E–138–
DEPARTMENT OF HEALTH AND Dated: March 29, 2017. 2008/0).
HUMAN SERVICES Melanie J. Pantoja, With respect to persons who have an
Program Analyst, Office of Federal Advisory obligation to assign their right, title and
National Institutes of Health Committee Policy. interest to the Government of the United
National Institute on Aging; Notice of [FR Doc. 2017–06553 Filed 4–3–17; 8:45 am] States of America, the patent rights in
Closed Meetings BILLING CODE 4140–01–P these inventions have been assigned to
the Government of the United States of
Pursuant to section 10(d) of the America.
Federal Advisory Committee Act, as DEPARTMENT OF HEALTH AND The prospective exclusive license
amended (5 U.S.C. App.), notice is HUMAN SERVICES territory may be worldwide and the
hereby given of the following meetings. field of use may be limited to:
National Institutes of Health ‘‘Treatment of Hypertriglyceridemia,
The meetings will be closed to the with or without concomitant metabolic
public in accordance with the Prospective Grant of Exclusive Patent syndrome’’.
provisions set forth in sections License: Development and The invention pertains to
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Commercialization of Peptides compositions and methods of use of
as amended. The grant applications and Promoting Lipid Efflux for the ApoC–II mimetic peptides with
the discussions could disclose Treatment of Hypertriglyceridemia, multiple amphipathic alpha helical
confidential trade secrets or commercial With or Without Concomitant domains that have the dual ability to
property such as patentable material, Metabolic Syndrome promote lipid efflux from cells and
and personal information concerning AGENCY: National Institutes of Health, stimulate lipoprotein lipase activity,
individuals associated with the grant HHS. without inducing toxicity. This notice is
applications, the disclosure of which made in accordance with 35 U.S.C. 209
ACTION: Notice.
would constitute a clearly unwarranted and 37 CFR part 404. The prospective
invasion of personal privacy. SUMMARY: The National Heart, Lung, and Exclusive Patent License will be royalty
Name of Committee: National Institute on Blood Institute (NHLBI), an institute of bearing and may be granted unless
Aging Initial Review Group, Biological Aging the National Institutes of Health; an within fifteen (15) days from the date of
Review Committee. agency within the Department of Health this published notice, the NHLBI Office
Date: May 30–31, 2017. and Human Services, is contemplating of Technology Transfer and
Time: 2:00 p.m. to 2:00 p.m. the grant of an exclusive patent license Development receives written evidence
asabaliauskas on DSK3SPTVN1PROD with NOTICES

Agenda: To review and evaluate grant to commercialize the invention(s) and argument that establishes that the
applications. embodied in the intellectual property grant of the license would not be
Place: Torrance Marriott Redondo Beach,
3635 Fashion Way, Torrance, CA 90503.
estate stated in the Summary consistent with the requirements of 35
Contact Person: Bita Nakhai, Ph.D., Information section of this notice to U.S.C. 209 and 37 CFR part 404.
Scientific Review Branch, National Institute Corvidia Therapeutics Inc. (Corvidia) Complete applications for a license in
on Aging, Gateway Bldg., 2C212, 7201 located in Waltham, MA and the prospective field of use that are
Wisconsin Avenue, Bethesda, MD 20814, incorporated under the laws of timely filed in response to this notice
301–402–7701, nakhaib@nia.nih.gov. Delaware. will be treated as objections to the grant

VerDate Sep<11>2014 16:21 Apr 03, 2017 Jkt 241001 PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 E:\FR\FM\04APN1.SGM 04APN1

Document Created: 2017-04-03 23:54:07
Document Modified: 2017-04-03 23:54:07

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
FR Citation		82 FR 16404

82 FR 16404 - Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

DEPARTMENT OF HEALTH AND HUMAN SERVICESCenters for Disease Control and Prevention

Federal Register Volume 82, Issue 63 (April 4, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention